Cord Blood Banking Leader Cryo-Cell Reports Fiscal Third Quarter 2026 Financial Results
Cryo-Cell reported fiscal Q3 2026 net income of $1.27 million, or $0.16 per share, up sharply from $749,000, or $0.09, a year earlier. Consolidated revenue was essentially flat at $7.82 million versus $7.83 million in the prior-year quarter, meaning the earnings improvement came from cost or margin dynamics rather than growth.
Key figures
- Eps
- 0.16
- Revenue
- $7.82 million
- Revenue Yoy
- approximately flat (-0.1% vs $7.83 million)
- Net income
- $1.27 million
- Prior year eps
- 0.09
- Specimens stored
- 250000
- Transplants provided
- 900
- Prior year net income
- $749,000
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.